Corneal Endothelial Cell Loss
Conditions
Keywords
corneal endothelium, Bevacizumab, Intravitreal injection, Confoscan
Brief summary
To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection
Detailed description
Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.
Interventions
None listed
Sponsors
Khon Kaen University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* aged between 20 and 80 years old * can come to regular follow up at 6 month * signed written consent forms * not have corneal scar, or glaucoma * history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit * high risk in cerebrovascular and cardiovascular diseases * Pregnancy and breastfeeding * can undergo confocal microspopy
Exclusion criteria
* History of intraocular surgery or ocular trauma during study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Corneal endothelium cell change after intravitreal Bevacizumab injection | 6 months | Measure the corneal endothelium cell using Confoscan4-Corneal confocal microscope in patient in retinal vascular clinic before and after treat with intravitreal Bevacizumab |
Secondary
| Measure | Time frame |
|---|---|
| Assess the complication after intravitreal Bevacizumab injection | 6 month |
Countries
Thailand
Contacts
Primary ContactKasem Yospaiboon, MD
Outcome results
None listed